MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wei, Yongbao ^a   Yang, Jinrui ^a   Yi, Lu ^a   Wang, Yinhuai ^a   Dong, Zhitao ^a   Liu, Ziting ^a   Ou Yang, Shifeng ^a   Wu, Hongtao ^a   Zhong, Zhaohui ^a   Yin, Zhuo ^a   Zhou, Keqin ^a   Gao, Yunliang ^a   Yan, Bin ^a   Wang, Zhao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN223 MICRORNA, HUMAN; SEPT6 PROTEIN, HUMAN; SEPTIN;

GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; SEPTINS; UP-REGULATION;

EID: 84929912742     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07546     Document Type: Article

References (47)

1. Shaikhibrahim, Z. et al. Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation. Int J Mol Med 28, 799-807 (2011).
2. Hudson, B. D., Kulp, K. S. & Loots, G. G. Prostate cancer invasion and metastasis: insights from mining genomic data. Brief Funct Genomics 12, 397-410 (2013).
3. Menegaux, F. et al. Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer 14, 106 (2014).
4. Catto, J. W. et al. Micro RNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59, 671-81 (2011).
5. He, H. C. et al. Micro RNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett 586, 2451-8 (2012).
6. Mlcochova, H., Hezova, R., Stanik, M. & Slaby, O. Urine micro RNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 32, 41.e1-9 (2014).
7. Fendler, A., Stephan, C., Yousef, G. M. & Jung, K. Micro RNAs as regulators of signal transduction in urological tumors. Clin Chem 57, 954-68 (2011).
8. Schaefer, A. et al. Micro RNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol 28, 4-13 (2010).
9. Coppola, V., De Maria, R. & Bonci, D. Micro RNAs and prostate cancer. Endocr Relat Cancer 17, F1-17 (2010).
10. Wang, H., Peng, W., Ouyang, X., Li, W. & Dai, Y. Circulating micro RNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res 160, 198-206 (2012).
11. Bloomston, M. et al. Micro RNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-8 (2007).
12. Petrocca, F. et al. E2F1-regulated micro RNAs impair TGFbeta-dependent cellcycle arrest and apoptosis in gastric cancer. Cancer Cell 13, 272-86 (2008).
13. Li, X. et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9, 824-33 (2011).
14. Li, B. S. et al. Plasma micro RNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 7, e41629 (2012).
15. Jia, Z., Wang, K., Wang, G., Zhang, A. & Pu, P. MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PLoS One 8, e55008 (2013).
16. Zhang, C. et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56, 1871-9 (2010).
17. Qi, P. et al. Serum micro RNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 6, e28486 (2011).
18. Zhou, J. et al. Plasma micro RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29, 4781-8 (2011).
19. Yang, M. et al. Microvesicles secreted by macrophages shuttle invasionpotentiating micro RNAs into breast cancer cells. Mol Cancer 10, 117 (2011).
20. Chen, X. et al. Identification of ten serum micro RNAs from a genome-wide serum micro RNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130, 1620-8 (2012).
21. Jia, W. et al. Identification of four serum micro RNAs from a genome-wide serum micro RNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol Lett 6, 261-267 (2013).
22. Calin, G. A. et al. A Micro RNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353, 1793-801 (2005).
23. Fazi, F. et al. Epigenetic silencing of the myelopoiesis regulator micro RNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12, 457-66 (2007).
24. Zeng, X. et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 7, e46367 (2012).
25. Xu, J. et al. MiR-223/Ect2/p21 signaling regulates osteosarcoma cell cycle progression and proliferation. Biomed Pharmacother 67, 381-6 (2013).
26. Karakatsanis, A. et al. Expression of micro RNAs, miR-21, miR-31, miR-122, miR- 145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 52, 297-303 (2013).
27. Wang, Y. et al. Micro RNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 44, 191-7 (2010).
28. Gottardo, F. et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25, 387-92 (2007).
29. Han, Z. B. et al. Identification of recurrence-related micro RNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 6, 445-57 (2012).
30. Sanfiorenzo, C. et al. Two panels of plasma micro RNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One 8, e54596 (2013).
31. Achberger, S. et al. Circulating immune cell and micro RNA in patients with uveal melanoma developing metastatic disease. Mol Immunol 58, 182-6 (2014).
32. Laios, A. et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7, 35 (2008).
33. Bartel, D. P. Micro RNAs: target recognition and regulatory functions. Cell 136, 215-33 (2009).
34. Zardo, G. et al. Polycombs and micro RNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood 119, 4034-46 (2012).
35. Wong, Q. W. et al. Micro RNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135, 257-69 (2008).
36. Gong, B. et al. Caprin-1 is a novel micro RNA-223 target for regulating the proliferation and invasion of human breast cancer cells. Biomed Pharmacother 67, 629-36 (2013).
37. Nian, W. et al. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclindependent kinase 2. Oncol Lett 6, 359-366 (2013).
38. Dolat, L., Hu, Q. & Spiliotis, E. T. Septin functions in organ system physiology and pathology. Biol Chem 395, 123-41 (2014).
39. Liu, M., Shen, S., Chen, F., Yu, W. & Yu, L. Linking the septin expression with carcinogenesis. Mol Biol Rep 37, 3601-8 (2010).
40. Connolly, D., Abdesselam, I., Verdier-Pinard, P. & Montagna, C. Septin roles in tumorigenesis. Biol Chem 392, 725-38 (2011).
41. Peterson, E. A. & Petty, E. M. Conquering the complex world of human septins: implications for health and disease. Clin Genet 77, 511-24 (2010).
42. Mostowy, S. & Cossart, P. Septins: the fourth component of the cytoskeleton. Nat Rev Mol Cell Biol 13, 183-94 (2012).
43. Megonigal, M. D. et al. t(11;22)(q23;q11.2) In acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in Di George and velocardiofacial syndromes. Proc Natl Acad Sci U S A 95, 6413-8 (1998).
44. Osaka, M., Rowley, J. D. & Zeleznik-Le, N. J. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci U S A 96, 6428-33 (1999).
45. Look, A. T. Oncogenic transcription factors in the human acute leukemias. Science 278, 1059-64 (1997).
46. Amir, S., Golan, M. & Mabjeesh, N. J. Targeted knockdown of SEPT9-v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res 8, 643-52 (2010).
47. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-8 (2001).